Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00717925 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Study Title
Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin’s Lymphoma (NHL) (NCT00717925)

Trial Description
To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).

This trial is sponsored by Pfitzer. [1]

Study Data

  • Condition: B-Cell Lymphoma
  • Interventions:
    • Drugs used in this trial
      • Inotuzumab Ozogamicin (CMC-544)
  • Phase: I
  • Enrollment: 13
  • Start: March 2007
  • Completion: July 2008
  • Last verified: September 2010

Study Schematic 

NCT00717925 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Click here to Return to Drug map


Last Editorial review: July 10, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar